Everyday Health (EVDY) 10-Q 12 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 07, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Everyday Health, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		32,258,117
Amendment Flag	false
Entity Central Index Key	1,358,483
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 46,634	$ 50,729
Accounts receivable, net of allowance for doubtful accounts of $525 and $637 as of June 30, 2015 and December 31, 2014, respectively	61,823	68,007
Deferred tax asset	656	656
Prepaid expenses and other current assets	15,011	5,529
Total current assets	124,124	124,921
Property and equipment, net	25,915	25,502
Goodwill	142,157	127,115
Intangible assets, net	43,538	30,716
Other assets	5,622	5,237
Total assets	341,356	313,491
Current liabilities:
Accounts payable and accrued expenses	28,360	31,722
Deferred revenue	11,718	6,740
Current portion of long-term debt	5,081	3,000
Other current liabilities	921	965
Total current liabilities	46,080	42,427
Long-term debt	107,669	87,000
Deferred tax liabilities	7,153	6,673
Other long-term liabilities	5,434	4,105
Stockholders’ equity:
Preferred stock, $0.01 par value: 10,000,000 shares authorized at June 30, 2015 and December 31, 2014; no shares issued and outstanding at June 30, 2015 and December 31, 2014	0	0
Common stock, $0.01 par value: 90,000,000 shares authorized at June 30, 2015 and December 31, 2014; 31,930,333 and 31,489,196 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	318	314
Treasury stock	(55)	(55)
Additional paid-in capital	300,221	292,117
Accumulated deficit	(125,464)	(119,090)
Total stockholders’ equity	175,020	173,286
Total liabilities and stockholders’ equity	$ 341,356	$ 313,491

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Allowance for doubtful accounts (in Dollars)	$ 525	$ 637
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued	31,930,333	31,489,196
Common stock, shares outstanding	31,930,333	31,489,196
Common stock, shares authorized	90,000,000	90,000,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Advertising and sponsorship revenues	$ 50,225	$ 36,882	$ 86,563	$ 69,574
Premium services revenues	4,580	4,565	9,417	9,378
Total revenues	54,805	41,447	95,980	78,952
Operating expenses:
Cost of revenues	13,926	10,961	28,002	22,382
Sales and marketing	21,041	12,216	33,766	22,436
Product development	12,187	10,805	24,789	21,567
General and administrative	10,065	7,126	19,869	13,721
Total operating expenses	57,219	41,108	106,426	80,106
Income (loss) from operations	(2,414)	339	(10,446)	(1,154)
Interest expense, net	(1,426)	(585)	(2,379)	(2,448)
Other expense				(4,114)
Loss from operations before benefit (provision) for income taxes	(3,840)	(246)	(12,825)	(7,716)
Benefit (provision) for income taxes	5,534	(349)	6,451	(638)
Net income (loss)	1,694	(595)	(6,374)	(8,354)
Series G preferred stock deemed dividend		(8,079)		(8,079)
Net income (loss) attributable to common stockholders	$ 1,694	$ (8,674)	$ (6,374)	$ (16,433)
Net income (loss) attributable to common stockholders per common share:
Basic (in Dollars per share)	$ 0.05	$ (0.29)	$ (0.20)	$ (0.93)
Diluted (in Dollars per share)	$ 0.05	$ (0.29)	$ (0.20)	$ (0.93)
Weighted-average common shares outstanding:
Basic (in Shares)	31,755,107	29,802,970	31,640,967	17,670,809
Diluted (in Shares)	33,373,407	29,802,970	31,640,967	17,670,809

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - Jun. 30, 2015 - USD ($) $ in Thousands	Common Stock [Member]	Preferred Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2014	$ 314	$ 0	$ (55)	$ 292,117	$ (119,090)	$ 173,286
Balance (in Shares) at Dec. 31, 2014	31,489,196
Exercise of stock options	$ 2			1,724		1,726
Exercise of stock options (in Shares)	230,776
Common stock issued for settlement of restricted stock units, net of 747 shares withheld to satisfy income tax withholding obligations				(10)		(10)
Common stock issued for settlement of restricted stock units, net of 747 shares withheld to satisfy income tax withholding obligations (in Shares)	1,176
Exercise of warrants	$ 1			(1)
Issuance of common stock in connection with employee stock purchase plan	$ 1			1,147		1,148
Issuance of common stock in connection with employee stock purchase plan (in Shares)	109,304
Stock based compensation expense				5,244		5,244
Net loss					(6,374)	(6,374)
Balance at Jun. 30, 2015	$ 318	$ 0	$ (55)	$ 300,221	$ (125,464)	$ 175,020
Balance (in Shares) at Jun. 30, 2015	31,930,333
Exercise of warrants (in Shares)	99,881

Consolidated Statements of Sto6

Consolidated Statements of Stockholders' Equity (Parentheticals)	6 Months Ended
	Jun. 30, 2015shares
Common Stock [Member]
Shares withheld to satisfy income tax withholding obligations	747

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities
Net loss	$ (6,374)	$ (8,354)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	9,871	7,150
Provision for doubtful accounts		215
Stock-based compensation	5,244	4,019
Amortization and write-off of financing costs	251	4,239
Provision (benefit) for deferred income taxes	(120)	481
Changes in operating assets and liabilities:
Accounts receivable	10,590	9,522
Prepaid expenses and other current assets	(9,387)	(456)
Accounts payable and accrued expenses	(4,735)	(11,740)
Deferred revenue	4,780	1,347
Other current liabilities	63	(103)
Other long-term liabilities	1,531	618
Net cash provided by operating activities	11,714	6,938
Cash flows from investing activities
Additions to property and equipment, net	(6,572)	(7,441)
Proceeds from sale of business		400
Payment for business purchased, net of cash acquired	(32,747)
Payment of security deposits and other assets	84	47
Net cash used in investing activities	(39,235)	(6,994)
Cash flows from financing activities
Net proceeds from common stock issuance		70,622
Proceeds from the exercise of stock options	1,769	2,151
Principal payments on capital lease obligations	(361)	(308)
Tax withholdings related to net share settlements of restricted stock units (RSUs)	(10)
Payments of credit facility financing costs	(722)	(2,234)
Net cash provided by financing activities	23,426	38,898
Net increase (decrease) in cash and cash equivalents	(4,095)	38,842
Cash and cash equivalents, beginning of period	50,729	16,242
Cash and cash equivalents, end of period	46,634	55,084
Supplemental disclosure of cash flow information
Interest paid	1,271	2,867
Income taxes paid	150	163
Supplemental disclosure of non-cash investing and financing activities
Issuance of common stock for acquired business		919
Warrants issued in connection with website partner agreement		1,131
Capital lease obligations incurred		362
Reclassification of liability warrants to equity warrants		1,140
Former Revolving Credit Facility [Member]
Cash flows from financing activities
Repayments of principal		(30,000)
Former Term Loan [Member]
Cash flows from financing activities
Repayments of principal		(41,333)
Revolving Credit Facility [Member]
Cash flows from financing activities
Repayments of principal	(10,000)	(32,300)
Borrowings	25,000	32,300
Term Loan Facility [Member]
Cash flows from financing activities
Repayments of principal	(750)
Borrowings	$ 8,500	$ 40,000

Business

Business	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block [Abstract]
Business Description and Basis of Presentation [Text Block]	1. Business Everyday Health, Inc. (the “Company”) operates a portfolio of health and wellness websites and mobile applications that provides consumers, healthcare professionals, advertisers and partners with content and advertising-based services. The Company was incorporated in the State of Delaware in January 2002 as Agora Media Inc., and changed its name to Waterfront Media Inc. in January 2004. In January 2010, the Company changed its name to Everyday Health, Inc. to better align its corporate identity with the Everyday Health brand.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. The results of operations for companies acquired are included in the consolidated financial statements from the effective date of the acquisition. All significant intercompany accounts and transactions have been eliminated in consolidation. Interim Financial Statements The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) on the same basis as the audited consolidated financial statements for the year ended December 31, 2014 and, in the opinion of management, include all adjustments of a normal recurring nature considered necessary to present fairly the Company’s financial position, results of operations and cash flows for the interim periods ended June 30, 2015 and 2014. The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015 or any other future periods, due to seasonality and other business factors. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted under the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto for the year ended December 31, 2014, which are included in the Company’s Annual Report on Form 10-K filed with the SEC on March 5, 2015. Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience, current business factors and other available information. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition and deferred revenue, allowance for doubtful accounts, internal software development costs and website development costs, valuation of long-lived assets, goodwill and other intangible assets, income taxes and stock-based compensation. Reclassifications Certain reclassifications have been made to the prior period financial statements to conform to the June 30, 2015 presentation. Initial Public Offering On April 2, 2014, the Company closed its initial public offering of common stock (“IPO”). The IPO, including the additional shares issued and sold on April 30, 2014 pursuant to the underwriters’ exercise of their over-allotment option, resulted in net proceeds of $70,622, after deducting underwriting discounts and commissions and offering costs borne by the Company totaling $8,848. As a result of the IPO, the Company issued and sold 5,676,414 shares of common stock at a public offering price of $14.00 per share, and all of the Company’s redeemable convertible preferred stock outstanding automatically converted into an aggregate of 18,457,235 shares of common stock, including 577,055 additional shares of common stock related to the Series G redeemable convertible preferred stock ratchet provision. Revenue Recognition and Deferred Revenue The Company generates its revenue primarily through advertising and sponsorships, and premium services, including subscriptions and licensing fees. Advertising revenue is recognized in the period in which the advertisement is delivered. Revenue from sponsorships is recognized over the period the Company substantially satisfies its contractual obligations as required under the respective sponsorship agreements. When contractual arrangements contain multiple elements, revenue is allocated to each element based on its relative fair value determined using prices charged when elements are sold separately. In instances where individual deliverables are not sold separately, or when third-party evidence is not available, fair value is determined based on management’s best estimate of selling price. Subscriptions are generally paid in advance on a monthly, quarterly or annual basis. Subscription revenue, after deducting refunds and charge-backs, is recognized on a straight-line basis ratably over the subscription periods. Licensing revenue is generally recognized over the life of the contract. Deferred revenue relates to: (i) subscription fees for which amounts have been collected but for which revenue has not been recognized, and (ii) advertising and sponsorship fees and licensing fees billed in advance of when the revenue is to be earned. Cost of Revenues Cost of revenues consists principally of the expenses associated with aggregating the total audience across the Company’s portfolio of websites, including (i) royalty expenses for licensing content for certain websites within the portfolio and for the portion of advertising revenue the Company pays to the owners of certain other websites within the portfolio, and (ii) media costs associated with audience aggregation activities. Cost of revenues also includes credit card fees and service charges associated with subscription fees for the Company’s premium services. Media costs consist primarily of fees paid to online publishers, internet search companies and other media channels for search engine and database marketing, and display and television advertising. These media activities are attributable to revenue-generating and audience aggregation events, designed to increase the audience to the websites the Company operates, increase the number of subscribers to premium services and grow the Company’s registered user base. Other Expense There were no charges reflected as other expense in the six months ended June 30, 2015. In connection with the refinancing of its credit facilities in March 2014, the Company wrote-off unamortized deferred financing costs totaling $2,845 and incurred prepayment fees of $1,016, which, together with the mark-to-market adjustment on certain preferred stock warrants of $253, is reflected as other expense in the accompanying consolidated statements of operations for the six months ended June 30, 2014. Comprehensive Income The Company has no items of other comprehensive income, and accordingly net income (loss) is equal to comprehensive income (loss) for all periods presented. Fair Value of Financial Instruments Due to their short-term maturities, the carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses, approximate fair value. Cash equivalents principally consist of the Company’s investment in highly liquid money market funds. The fair value of these investment funds is based on quoted market prices, which are Level 1 inputs, pursuant to the fair value accounting standard, which establishes a framework for measuring fair value and requires disclosures about fair value measurements by establishing a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of the Company’s debt approximates the recorded amounts as the interest rates on the credit facilities are based on market interest rates. Property and Equipment Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, ranging from three to five years. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the lease term or the estimated useful life of the improvement. The Company incurs costs to develop software for internal use. The Company expenses all costs that relate to the planning and post-implementation phases of development as product development expense. Costs incurred in the application development phase, consisting principally of payroll and related benefits, are capitalized. Upon completion, the capitalized costs are amortized using the straight-line method over their estimated useful lives, which is generally three years. The Company also incurs costs to develop its websites and mobile applications. The Company expenses all costs that relate to the planning and post-implementation phases of development as product development expense. Costs incurred in the application development phase, consisting principally of third-party consultants and related charges, and the costs of content determined to provide a future economic benefit, are capitalized. Upon completion, the capitalized costs are amortized using the straight-line method over their estimated useful lives, which is generally three years. The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. There were no indicators of impairment of the Company’s property and equipment during the six months ended June 30, 2015 and 2014. Segment Information The Company and its subsidiaries are organized in a single operating segment, providing online health solutions, and the Company also has one reportable segment. Substantially all of the Company’s revenues are derived from U.S. sources. Recent Accounting Standards In April 2014, the Financial Accounting Standards Board (“FASB”) issued amended guidance for reporting discontinued operations. Under the new guidance, only disposals that represent a strategic shift having a material impact on an entity’s operations and financial results shall be reported as discontinued operations, with expanded disclosures. This amendment will be effective for the first annual reporting period beginning after December 15, 2015. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements. In May 2014, the FASB issued amended guidance for revenue recognition. This amendment provides a comprehensive new revenue recognition model. The core principle of the guidance is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. This amendment was originally to be effective for annual and interim periods beginning after December 15, 2016. In July 2015, the FASB approved a one year deferral of the effective date to December 15, 2017 and early adoption is permitted, but not before the original effective date of December 15, 2016. The standard permits the use of either the retrospective or cumulative effect transition method. The Company has not yet selected a transition method and is currently evaluating the effect that the new standard will have on the consolidated financial statements and related disclosures. In June 2014, the FASB issued updated guidance on stock compensation accounting requiring that a performance target that affects vesting and could be achieved after the requisite service period should be treated as a performance condition. Current GAAP does not contain explicit guidance on how to account for such share-based payments. This updated guidance is effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. Early adoption is permitted. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements. In April 2015, the FASB issued updated guidance on the presentation of debt issuance costs in financial statements. The new guidance requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. This guidance will be effective for the Company beginning in the first quarter of 2016 on a retrospective basis for all periods presented, with early adoption optional. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block Supplement [Abstract]
Mergers, Acquisitions and Dispositions Disclosures [Text Block]	3. Acquisitions In March 2015, the Company acquired 100% of the limited liability company membership interests of Cambridge BioMarketing Group, LLC (“Cambridge”), a provider of strategic launch and marketing solutions for orphan and rare disease products, for a total purchase price of $32,273, of which $24,273 was paid in cash at closing. The remaining $8,000 obligation at closing was comprised of convertible notes that could either convert into shares of the Company’s common stock or be repaid in cash by May 15, 2015, at the discretion of the Company. The Company paid the $8,000 obligation in cash on May 14, 2015. The total purchase price is subject to any working capital adjustments that may arise. In addition to the purchase price described above, the former members of Cambridge are eligible to receive up to an additional $5,000 in cash based on Cambridge’s achievement of certain revenue and Adjusted EBITDA targets for 2015. This earn-out payment is contingent upon the continued employment with the Company of certain former members of Cambridge at the time the earn-out payment is due to be paid in the first quarter of 2016. The Company records any such earn-out as compensation expense for the applicable period. As of June 30, 2015, the Company accrued $2,270 in compensation expense for this earn-out, which is included in accounts payable and accrued expenses on the accompanying consolidated balance sheet. The Company expects that the acquisition will broaden its strategic marketing and communications solutions to pharmaceutical brands targeting orphan and rare disease segments in the market. The acquisition was accounted for as a business combination and, accordingly, the purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed on a preliminary basis based on the respective fair values. The results of operations of Cambridge have been included in the consolidated financial statements of the Company from March 20, 2015, the closing date of the acquisition. The consolidated statements of operations for the three and six months ended June 30, 2015 include revenue of $5,357 and $6,045, respectively, and net income of $1,709 and $1,987, respectively, attributable to Cambridge. Additionally, for the three and six months ended June 30, 2015, acquisition-related costs of $17 and $186, respectively, are included in general and administrative expenses in the accompanying consolidated statement of operations. Supplemental information on an unaudited pro forma basis, as if the acquisition of Cambridge had been consummated on January 1, 2014, is presented as follows: Unaudited Pro Forma Results Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Revenue $ 54,805 $ 44,987 $ 100,247 $ 86,038 Net income (loss) $ 1,717 $ (600 ) $ (6,044 ) $ (8,498) The unaudited pro forma results give effect to pro forma events that are directly attributable to the assumed acquisition, factually supportable, and expected to have a continuing impact on the combined results. The unaudited pro forma results include adjustments primarily related to amortization expense associated with acquired intangible assets and incremental interest expense related to additional borrowings on the Company’s Credit Facility used to fund the acquisition. The unaudited pro forma results are not necessarily indicative of or intended to represent the results that would have been achieved had the transaction been consummated as of the date indicated or that may be achieved in future periods. The following table summarizes the preliminary allocation of the assets acquired and liabilities assumed based on their fair values on the acquisition date. The fair values presented are based on a preliminary valuation and are subject to adjustment during a measurement period of up to one year from the acquisition date. The measurement period provides the Company with the ability to adjust the fair values of acquired assets for new information that is obtained about circumstances that existed as of the acquisition date. Accounts receivable $ 4,406 Other current assets 137 Property and equipment 783 Goodwill 15,576 Intangible assets 14,280 Accounts payable and accrued expenses (2,659 ) Deferred revenue (197 ) Other current liabilities (53 ) Total consideration paid $ 32,273

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	4. Goodwill and Other Intangible Assets During the six months ended June 30, 2015, goodwill of $15,576 and definite-lived intangible assets of $14,280 were recorded in connection with the Cambridge acquisition (see Note 3). The preliminary value of the intangible assets acquired in connection with the Cambridge acquisition consists of customer relationships of $8,810 and trade names of $5,470, each of which has an estimated useful life of 10 years. Additionally, goodwill decreased by $534 and definite-lived intangible assets increased by $1,470 during the subsequent measurement period from a working capital adjustment and revision to the preliminary fair value allocation of assets acquired and liabilities assumed related to a November 2014 acquisition. The carrying value of the Company’s goodwill was $142,157 as of June 30, 2015. Goodwill is tested for impairment on an annual basis as of October 1, and whenever events or circumstances indicate that the carrying value of the asset may not be recoverable. Application of the impairment test requires judgment and results in impairment being recognized if the carrying value of the asset exceeds its fair value. No indicators of impairment were noted during or since the Company’s last evaluation of goodwill at October 1, 2014. Similarly, the Company’s definite-lived intangible assets with a net carrying value of $43,538 at June 30, 2015, consisting principally of trade names and customer relationships, is reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. There were no indicators of impairment of the Company’s definite-lived intangible assets during the six months ended June 30, 2015 and 2014. Definite-lived intangible assets consist of the following: June 30, 2015 December 31, 2014 Gross carrying amount Accumulated amortization Net carrying amount Weighted- average remaining useful life (1) Gross carrying amount Accumulated amortization Net carrying amount Weighted- average remaining useful life (1) Customer relationships $ 37,580 $ (12,640 ) $ 24,940 9.3 $ 27,300 $ (11,247 ) $ 16,053 9.5 Trade names 24,085 (5,626 ) 18,459 7.1 18,615 (4,370 ) 14,245 6.5 Other intangibles 3,900 (3,761 ) 139 0.3 3,900 (3,482 ) 418 0.7 Total $ 65,565 $ (22,027 ) $ 43,538 $ 49,815 $ (19,099 ) $ 30,716 (1) The calculation of the weighted-average remaining useful life is based on weighting the net book value of each asset in its group, and applying the weight to its respective remaining amortization period. Amortization expense relating to the definite-lived intangible assets totaled $1,709 and $546 for the three months ended June 30, 2015 and 2014, respectively, and $2,928 and $1,091 for the six months ended June 30, 2015 and 2014, respectively, and is included in general and administrative expense in the accompanying consolidated statements of operations. Future amortization expense of the intangible assets is estimated to be as follows: Year ending December 31: 2015 (July 1st to December 31st) $ 2,983 2016 5,520 2017 5,512 2018 5,323 2019 5,323 Thereafter 18,877 Total $ 43,538

Long-Term Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block [Abstract]
Long-term Debt [Text Block]	5. Long-Term Debt The Company entered into a credit facility agreement with a syndicated bank group in March 2014, which replaced its then-existing credit facility. The new credit facility consisted of a revolver (“Revolver”) with a maximum borrowing limit of $35,000 and a term loan (“Term Loan”) of $40,000. In November 2014, in connection with an acquisition, the credit facility was amended and restated to, among other things, (i) increase the maximum borrowing limit of the Revolver from $35,000 to $55,000; (ii) increase the Term Loan from $39,000 outstanding as of such date to $60,000; (iii) extend the maturity date of the Term Loan and the due date of principal on the Revolver from March 2019 to November 2019; and (iv) effect certain modifications to the covenants and terms set forth in the credit facility agreement. In March 2015, the amended and restated credit facility was amended twice (as amended, the “Credit Facility”) to, among other things, (i) consent to the acquisition of Cambridge, (ii) increase the Term Loan from $59,250 outstanding as of such date to $67,750; (iii) increase the maximum borrowing limit of the Revolver from $55,000 to $82,250; and (iv) effect certain modifications to the covenants and terms set forth in the Credit Facility agreement. All other materials terms of the Credit Facility, including the applicable maturity dates, remained unchanged by the March 2015 amendments. The repayment terms of the Revolver provide for quarterly interest payments, with the principal being due in full in November 2019. The repayment terms of the Term Loan provide for quarterly interest and principal payments, with a maturity date of November 2019. The interest rate on the Credit Facility is equal to the London Inter-Bank Offered Rate, or LIBOR, plus a variable rate ranging from 2.75% to 4.0% depending on the Company’s consolidated leverage ratio, as defined in the Credit Facility agreement, and there is a 0.50% commitment fee on the unused portion of the Revolver. As of June 30, 2015, the interest rate on the Credit Facility was 4.28%. As of June 30, 2015, there was $67,750 outstanding on the Term Loan and $45,000 outstanding on the Revolver, with $37,250 available to be drawn on the Revolver. The Credit Facility contains certain financial and operational covenants, including requirements to maintain a minimum consolidated fixed charge coverage ratio and a maximum consolidated leverage ratio, each as defined in the Credit Facility agreement, as well as restrictions on certain types of dispositions, mergers and acquisitions, indebtedness, investments, liens and capital expenditures, issuance of capital stock and the Company’s ability to pay dividends. The Credit Facility is secured by a first priority security interest in substantially all of the Company’s existing and future assets. The Company was in compliance with the financial and operational covenants of the Credit Facility as of June 30, 2015. In connection with the March 2014 refinancing and the November 2014 amendment, the Company incurred financing costs totaling $2,899 and, in connection with the March 2015 amendments, the Company incurred financing costs of $722, each of which has been deferred and is being amortized using the effective interest rate method through the final maturities of the Credit Facility. Deferred financing costs are recorded in other assets in the accompanying consolidated balance sheets. Amortization expense relating to deferred financing costs is included in interest expense in the accompanying consolidated statements of operations.

Common Stock and Preferred Stoc

Common Stock and Preferred Stock	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	6. Common Stock and Preferred Stock As of June 30, 2015 and December 31, 2014, there were no shares of preferred stock issued and outstanding. The redeemable convertible preferred stock, Series A-G (collectively, the “Preferred Stock”), which was outstanding at the time of the Company’s IPO, fully converted to common stock in connection with the IPO. In March 2014, the Company’s Board of Directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation effecting a 1-for-1.5 reverse stock split of the Company’s issued and outstanding shares of common stock. The par value of the common stock was not adjusted as a result of the reverse stock split. All issued and outstanding common stock and per share amounts contained in the Company’s consolidated financial statements and related notes thereto have been retroactively adjusted to reflect this reverse stock split for all periods presented. The reverse stock split was effected on March 14, 2014. In April 2014, in connection with the closing of the Company’s IPO, the Company filed an amended and restated certificate of incorporation with the Secretary of State of the State of Delaware that amended and restated in its entirety the Company’s certificate of incorporation to, among other things, increase the total number of shares of the Company’s common stock that the Company is authorized to issue to 90,000,000, eliminate all references to the various series of preferred stock that were previously authorized (including certain protective measures held by the various series of preferred stock), and to authorize up to 10,000,000 shares of undesignated preferred stock that may be issued from time to time with terms to be set by the Company’s Board of Directors, which rights could be senior to those of the Company’s common stock.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7. Stock-Based Compensation The Company has granted non-statutory stock options and restricted stock unit awards to employees, directors and consultants of the Company pursuant to its 2003 Stock Option Plan, as amended (the “2003 Plan”), or 2014 Equity Incentive Plan (the “2014 Plan”), which became effective immediately upon the signing of the underwriting agreement related to the IPO on March 27, 2014. Upon the effectiveness of the 2014 Plan, no additional awards have been or will be granted under the 2003 Plan. The 2014 Plan provides for the grant of stock options, restricted stock units, and other awards based on the Company’s common stock. As of June 30, 2015, 440,210 shares have been reserved for issuance under the 2014 Plan. The number of shares of common stock reserved for issuance under the 2014 Plan is subject to an automatic increase on January 1 of each year through January 1, 2024, by the lesser of (a) 4% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year and (b) a number of shares determined by the Board of Directors. Stock Options The following table summarizes stock option activity for the six months ended June 30, 2015: Number of options Weighted- average exercise price Weighted- average remaining contractual life (years) Aggregate intrinsic value Outstanding at December 31, 2014 5,893,698 $ 9.94 6.48 $ 29,249 Granted 785,150 12.24 Exercised (230,776 ) 7.48 Cancelled (167,002 ) 12.54 Outstanding at June 30, 2015 6,281,070 $ 10.26 5.79 $ 19,579 Exercisable at June 30, 2015 3,949,409 $ 8.62 4.32 $ 17,436 Proceeds from the exercise of options and the total intrinsic value of the options exercised were $1,309 and $792, respectively, for the three months ended June 30, 2015, and $983 and $2,312, respectively, for the three months ended June 30, 2014. Proceeds from the exercise of options and the total intrinsic value of the options exercised were $1,769 and $1,276, respectively, for the six months ended June 30, 2015, and $2,151 and $3,225, respectively, for the six months ended June 30, 2014. The weighted-average fair value per share at date of grant for options granted was $5.48 and $7.68 during the six months ended June 30, 2015 and 2014, respectively. The fair value of options granted is estimated on the date of grant using the Black-Scholes option pricing model and recognized in expense over the vesting period of the options using the graded attribution method. The following table presents the weighted-average assumptions used to estimate the fair value of options granted in the six months ended June 30, 2015 and 2014: 2015 2014 Volatility 44.06 % 49.74 % Expected life (years) 6.25 6.25 Risk-free interest rate 1.73 % 1.91 % Dividend yield — — The expected stock price volatilities are estimated based on historical realized volatilities of comparable publicly traded company stock prices over a period of time commensurate with the expected term of the option award. The expected life represents the period of time for which the options granted are expected to be outstanding. The Company used the simplified method for determining expected life for options qualifying for treatment due to the limited history the Company currently has with option exercise activity. The risk-free interest rate is based on the U.S. Treasury yield curve for periods equal to the expected term of the options on the grant date. Total stock-based compensation expense related to stock options was $1,511 and $2,543 for the three months ended June 30, 2015 and 2014, respectively, and $3,469 and $3,612 for the six months ended June 30, 2015 and 2014, respectively. At June 30, 2015, there was approximately $6,835 of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.37 years. The total fair value of stock options vested during the six months ended June 30, 2015 and 2014 was $3,668 and $1,974, respectively. Restricted Stock Unit Awards The Company’s restricted stock unit awards (“RSUs”) are agreements to issue shares of the Company’s common stock to employees in the future, upon the satisfaction of certain vesting conditions, which cause them to be subject to risk of forfeiture and restrict the awardholder’s ability to sell or otherwise transfer such RSUs until they vest. Generally, the Company’s RSU grants vest over three years from the grant date subject to continued employment on the applicable vesting dates. The following table summarizes the unvested RSU activity for the six months ended June 30, 2015: Number of Weighted Outstanding at December 31, 2014 — $ — Granted (1) 573,724 12.01 Vested (1,923 ) 11.99 Cancelled (24,397 ) 11.99 Outstanding at June 30, 2015 547,404 $ 12.01 (1) RSUs granted during the six months ended June 30, 2015 includes the grant of 40,000 units of performance-based RSUs that are dependent upon the Company meeting certain performance criteria. Total stock-based compensation expense related to RSUs was $1,261 and $1,524 for the three and six months ended June 30, 2015, respectively. As RSUs were issued for the first time in March 2015, there was no stock-based compensation expense related to RSUs in 2014. At June 30, 2015, there was approximately $4,706 of unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of 1.38 years. 2014 Employee Stock Purchase Plan The 2014 Employee Stock Purchase Plan (“ESPP”), which became effective immediately upon the signing of the underwriting agreement related to the IPO on March 27, 2014, authorized the issuance of 500,000 shares of the Company’s common stock pursuant to purchase rights granted to employees. The number of shares of common stock reserved for issuance under the ESPP will automatically increase on January 1 of each calendar year from January 1, 2015 through January 1, 2024 by the least of (a) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (b) 400,000 shares and (c) a number determined by the Board of Directors that is less than (a) and (b). Unless otherwise determined by the Board of Directors, common stock will be purchased for participating employees at a price per share equal to the lower of (a) 85% of the fair market value of a share of the common stock on the first date of an offering, or (b) 85% of the fair market value of a share of the common stock on the date of purchase. Generally, all regular employees may participate in the ESPP and may contribute, through payroll deductions, up to 15% of their earnings toward the purchase of common stock under the ESPP. Under the terms of the ESPP, there are defined limitations as to the amount and value of common stock that can be purchased by each employee. The Company’s second purchase period commenced in November 2014 and ended in May 2015. During the three months ended June 30, 2015, employees purchased 109,304 shares of common stock pursuant to the ESPP at an exercise price of $10.51. As of June 30, 2015, 567,403 shares of common stock were reserved for future issuance under the ESPP. For the three months ended June 30, 2015 and 2014, charges incurred under the ESPP totaled $(20) and $407, respectively. For the six months ended June 30, 2015 and 2014, charges incurred under the ESPP totaled $251 and $407, respectively. There was $365 of total unrecognized compensation cost related to purchase rights under the ESPP as of June 30, 2015. This cost is expected to be recognized over a weighted average period of less than one year.

Net Income (Loss) Attributable

Net Income (Loss) Attributable to Common Stockholders per Common Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	8. Net Income (Loss) Attributable to Common Stockholders per Common Share Basic net income (loss) attributable to common stockholders per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, adjusted to reflect potentially dilutive securities. Potentially dilutive securities consist of incremental shares issuable upon the assumed exercise of stock options, restricted stock units, and warrants using the treasury stock method, and employee withholdings to purchase common stock under the ESPP. Due to the net losses for the three months ended June 30, 2014 and six months ended June 30, 2015 and 2014, the Company had outstanding options, warrants, restricted stock units, and ESPP withholdings which were not included in the computation of diluted net loss per common share, as the effects would have been anti-dilutive. The basic and diluted net income (loss) attributable to common stockholders per common share is calculated as follows for the periods presented: Three months ended Six months ended June 30, June 30, 2015 2014 2015 2014 Numerator: Net income (loss) $ 1,694 $ (595 ) $ (6,374 ) $ (8,354 ) Series G preferred stock deemed dividend — (8,079 ) — (8,079 ) Net income (loss) attributable to common stockholders $ 1,694 $ (8,674 ) $ (6,374 ) $ (16,433 ) Denominator: Weighted-average number of common shares outstanding for basic net income (loss) attributable to common stockholders per common share 31,755,107 29,802,970 31,640,967 17,670,809 Dilutive securities: Stock option awards 1,476,550 — — — Restricted stock units 97,232 — — — Warrants to purchase common stock 37,320 — — — Employee stock purchase plan 7,198 — — — Total weighted-average diluted shares 33,373,407 29,802,970 31,640,967 17,670,809 Basic net income (loss) attributable to common stockholders per common share $ 0.05 $ (0.29 ) $ (0.20 ) $ (0.93 ) Diluted net income (loss) attributable to common stockholders per common share $ 0.05 $ (0.29 ) $ (0.20 ) $ (0.93 ) The following securities were outstanding for the periods presented below and have been excluded from the calculation of diluted net income (loss) attributable to common stockholders per common share because the effect is anti-dilutive: Three months ended Six months ended June 30, June 30, 2015 2014 2015 2014 Warrants to purchase common stock (1) — 422,153 110,080 495,807 Warrants to purchase redeemable convertible preferred stock (1) — 148,650 — 148,650 Redeemable convertible preferred stock (1) — 589,456 — 13,632,402 Stock option awards 2,496,032 4,984,276 4,072,625 5,077,505 Unvested RSU awards — — 362,142 — Employee stock purchase plan — 21,140 50,444 10,628 Total weighted-average anti-dilutive securities 2,496,032 6,165,675 4,595,291 19,364,992 (1) Upon closing of the IPO on April 2, 2014, all of the Company's outstanding redeemable convertible preferred stock automatically converted into shares of common stock. In addition, the outstanding warrants to purchase redeemable convertible preferred stock automatically converted into warrants to purchase common stock, or were automatically exercised upon closing of the IPO.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	9. Income Taxes The Company’s annual net tax provision is generally comprised of a deferred tax provision pertaining to basis differences in indefinite lived intangible assets that cannot be offset by current year deferred tax assets, as well as, to a much lesser extent, a current tax provision for federal, state, local and foreign taxes. Effective March 31, 2015, the tax provision (benefit) for interim periods is determined using an estimate of the Company’s annual effective tax rate (“AETR”), adjusted for discrete items arising in the quarter, as applicable. Based on the estimated AETR, the deferred tax provision and a one-time tax benefit of $601 related to the release of a valuation allowance from finalizing the purchase price valuation of a November 2014 acquisition (see Note 4), the Company recorded a net tax benefit of $5,534 and $6,451 for the three and six months ended June 30, 2015, respectively, which is expected to be realized in the current year. The Company’s AETR during the three months ended June 30, 2015 increased as compared to March 31, 2015 due to a decrease in projected annual pretax income for 2015, primarily related to earnout and other acquisition related charges. In each quarter, the Company’s estimate of the AETR is updated and any changes are recognized in the interim period in which the change occurs. In interim periods prior to March 31, 2015, the tax provision was based upon the estimated deferred and current tax provision for the year rather than the estimated AETR, as the Company had historically experienced pretax losses in certain quarters and pretax income in others, and the annual results were expected to be at or near breakeven, and believed that using an AETR would result in significant variances in the customary relationship between income tax expense (benefit) and pretax income or loss in interim periods. The Company’s deferred tax assets relate primarily to net operating loss (“NOL”) carryforwards and to a smaller extent stock based compensation and other items. The Company has provided a valuation allowance against deferred tax assets to the extent the Company has determined that it is more likely than not that such net deferred tax assets will not be realizable. In determining realizability, the Company considered various factors including historical profitability and reversing temporary differences, exclusive of indefinite-lived intangibles. The Company’s deferred tax liabilities arose primarily from basis differences in indefinite-lived intangible assets that cannot be offset by current year deferred tax assets. At December 31, 2014, the Company had approximately $107,000 of NOL carryforwards available to offset future taxable income, which expire from 2020 through 2033. The full utilization of these losses in the future is dependent upon the Company’s ability to generate taxable income and may also be limited due to ownership changes, as defined under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended. The Company’s NOL carryforwards at December 31, 2014 included $7,433 of income tax deductions related to equity compensation that are greater than the compensation recognized for financial reporting, which will be reflected as a credit to additional paid-in capital as realized. The Company is subject to taxation in the U.S. and various federal, state, local and foreign jurisdictions. In April 2015, an audit of the Company’s U.S. Federal tax returns for the years ended December 31, 2011 and 2012 was concluded, with no changes or assessments. As of June 30, 2015, none of the Company’s other tax returns have been examined by any income taxing authority. The Company is not subject to U.S. federal, state or non-U.S. income tax examinations by tax authorities for years prior to 2010. However, to the extent U.S. federal and state NOL carryforwards are utilized, the use of NOLs could be subject to examination by the tax authorities. The Company believes that it has appropriate support for the income tax positions taken and to be taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on assessment of many factors, including past experience and interpretations of tax law. The Company regularly assesses the adequacy of its income tax contingencies in accordance with ASC 740. As a result, the Company may adjust its income tax contingency liabilities for the impact of new facts and developments, such as changes in interpretations of relevant tax law and assessments from taxing authorities.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	10. Commitments and Contingencies The Company is subject to certain claims that have arisen in the ordinary conduct of business. Based on the advice of counsel and an assessment of the nature and status of any potential claim, and taking into account any accruals the Company may have established for them, the Company currently believes that any liabilities ultimately resulting from such claims will not, individually or in the aggregate, have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	11. Subsequent Events On August 6, 2015, the Company acquired 100% of the limited liability company membership interests of Tea Leaves Health, LLC, a Georgia limited liability company (“Tea Leaves”), a provider of a SaaS-based marketing and analytics platform for hospital systems to identify and engage consumers and physicians, for a purchase price of $30,000. The purchase price consists of (i) $15,000 paid at closing in cash and (ii) $15,000 to be paid within six (6) months of closing, in the Company’s discretion, in cash, shares of Company common stock or a combination of cash and shares of Company common stock. The purchase price is subject to working capital and other adjustments as set forth in the purchase agreement. In addition to the purchase price described above, the former members of Tea Leaves are eligible to receive an additional $20,000 (50% in cash and 50% in shares of Company common stock) in the first quarter of 2017, based on Tea Leaves’ achievement of a specified financial target as of the end of 2016. The Company expects that the Tea Leaves acquisition will enable the Company to offer an integrated suite of solutions that will allow hospital systems to target both consumers and physicians and to provide measurable return on investment for their strategic planning and marketing efforts. Based upon the timing of the acquisition subsequent to the end of the most recent quarter, the initial accounting for the acquisition is incomplete at this time as the Company is in the process of determining the fair values of the net assets acquired and goodwill resulting from the acquisition. The Company has completed an evaluation of all subsequent events through the issuance date of these financial statements and concluded that other than the above matter, no subsequent events occurred that required recognition to the financial statements or disclosures in the notes to the consolidated financial statements.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. The results of operations for companies acquired are included in the consolidated financial statements from the effective date of the acquisition. All significant intercompany accounts and transactions have been eliminated in consolidation.
Interim Financial Statement [Policy Text Block]	Interim Financial Statements The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) on the same basis as the audited consolidated financial statements for the year ended December 31, 2014 and, in the opinion of management, include all adjustments of a normal recurring nature considered necessary to present fairly the Company’s financial position, results of operations and cash flows for the interim periods ended June 30, 2015 and 2014. The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015 or any other future periods, due to seasonality and other business factors. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted under the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto for the year ended December 31, 2014, which are included in the Company’s Annual Report on Form 10-K filed with the SEC on March 5, 2015.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience, current business factors and other available information. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition and deferred revenue, allowance for doubtful accounts, internal software development costs and website development costs, valuation of long-lived assets, goodwill and other intangible assets, income taxes and stock-based compensation.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain reclassifications have been made to the prior period financial statements to conform to the June 30, 2015 presentation.
Sale of Stock, Description of Transaction	Initial Public OfferingOn April 2, 2014, the Company closed its initial public offering of common stock (“IPO”). The IPO, including the additional shares issued and sold on April 30, 2014 pursuant to the underwriters’ exercise of their over-allotment option, resulted in net proceeds of $70,622, after deducting underwriting discounts and commissions and offering costs borne by the Company totaling $8,848. As a result of the IPO, the Company issued and sold 5,676,414 shares of common stock at a public offering price of $14.00 per share, and all of the Company’s redeemable convertible preferred stock outstanding automatically converted into an aggregate of 18,457,235 shares of common stock, including 577,055 additional shares of common stock related to the Series G redeemable convertible preferred stock ratchet provision.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition and Deferred Revenue The Company generates its revenue primarily through advertising and sponsorships, and premium services, including subscriptions and licensing fees. Advertising revenue is recognized in the period in which the advertisement is delivered. Revenue from sponsorships is recognized over the period the Company substantially satisfies its contractual obligations as required under the respective sponsorship agreements. When contractual arrangements contain multiple elements, revenue is allocated to each element based on its relative fair value determined using prices charged when elements are sold separately. In instances where individual deliverables are not sold separately, or when third-party evidence is not available, fair value is determined based on management’s best estimate of selling price. Subscriptions are generally paid in advance on a monthly, quarterly or annual basis. Subscription revenue, after deducting refunds and charge-backs, is recognized on a straight-line basis ratably over the subscription periods. Licensing revenue is generally recognized over the life of the contract. Deferred revenue relates to: (i) subscription fees for which amounts have been collected but for which revenue has not been recognized, and (ii) advertising and sponsorship fees and licensing fees billed in advance of when the revenue is to be earned.
Cost of Sales, Policy [Policy Text Block]	Cost of Revenues Cost of revenues consists principally of the expenses associated with aggregating the total audience across the Company’s portfolio of websites, including (i) royalty expenses for licensing content for certain websites within the portfolio and for the portion of advertising revenue the Company pays to the owners of certain other websites within the portfolio, and (ii) media costs associated with audience aggregation activities. Cost of revenues also includes credit card fees and service charges associated with subscription fees for the Company’s premium services. Media costs consist primarily of fees paid to online publishers, internet search companies and other media channels for search engine and database marketing, and display and television advertising. These media activities are attributable to revenue-generating and audience aggregation events, designed to increase the audience to the websites the Company operates, increase the number of subscribers to premium services and grow the Company’s registered user base.
Other Income and Other Expense Disclosure [Text Block]	Other Expense There were no charges reflected as other expense in the six months ended June 30, 2015. In connection with the refinancing of its credit facilities in March 2014, the Company wrote-off unamortized deferred financing costs totaling $2,845 and incurred prepayment fees of $1,016, which, together with the mark-to-market adjustment on certain preferred stock warrants of $253, is reflected as other expense in the accompanying consolidated statements of operations for the six months ended June 30, 2014.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income The Company has no items of other comprehensive income, and accordingly net income (loss) is equal to comprehensive income (loss) for all periods presented.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Due to their short-term maturities, the carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses, approximate fair value. Cash equivalents principally consist of the Company’s investment in highly liquid money market funds. The fair value of these investment funds is based on quoted market prices, which are Level 1 inputs, pursuant to the fair value accounting standard, which establishes a framework for measuring fair value and requires disclosures about fair value measurements by establishing a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of the Company’s debt approximates the recorded amounts as the interest rates on the credit facilities are based on market interest rates.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, ranging from three to five years. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the lease term or the estimated useful life of the improvement. The Company incurs costs to develop software for internal use. The Company expenses all costs that relate to the planning and post-implementation phases of development as product development expense. Costs incurred in the application development phase, consisting principally of payroll and related benefits, are capitalized. Upon completion, the capitalized costs are amortized using the straight-line method over their estimated useful lives, which is generally three years. The Company also incurs costs to develop its websites and mobile applications. The Company expenses all costs that relate to the planning and post-implementation phases of development as product development expense. Costs incurred in the application development phase, consisting principally of third-party consultants and related charges, and the costs of content determined to provide a future economic benefit, are capitalized. Upon completion, the capitalized costs are amortized using the straight-line method over their estimated useful lives, which is generally three years. The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. There were no indicators of impairment of the Company’s property and equipment during the six months ended June 30, 2015 and 2014.
Segment Reporting, Policy [Policy Text Block]	Segment Information The Company and its subsidiaries are organized in a single operating segment, providing online health solutions, and the Company also has one reportable segment. Substantially all of the Company’s revenues are derived from U.S. sources
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Standards In April 2014, the Financial Accounting Standards Board (“FASB”) issued amended guidance for reporting discontinued operations. Under the new guidance, only disposals that represent a strategic shift having a material impact on an entity’s operations and financial results shall be reported as discontinued operations, with expanded disclosures. This amendment will be effective for the first annual reporting period beginning after December 15, 2015. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements. In May 2014, the FASB issued amended guidance for revenue recognition. This amendment provides a comprehensive new revenue recognition model. The core principle of the guidance is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. This amendment was originally to be effective for annual and interim periods beginning after December 15, 2016. In July 2015, the FASB approved a one year deferral of the effective date to December 15, 2017 and early adoption is permitted, but not before the original effective date of December 15, 2016. The standard permits the use of either the retrospective or cumulative effect transition method. The Company has not yet selected a transition method and is currently evaluating the effect that the new standard will have on the consolidated financial statements and related disclosures. In June 2014, the FASB issued updated guidance on stock compensation accounting requiring that a performance target that affects vesting and could be achieved after the requisite service period should be treated as a performance condition. Current GAAP does not contain explicit guidance on how to account for such share-based payments. This updated guidance is effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. Early adoption is permitted. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements. In April 2015, the FASB issued updated guidance on the presentation of debt issuance costs in financial statements. The new guidance requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. This guidance will be effective for the Company beginning in the first quarter of 2016 on a retrospective basis for all periods presented, with early adoption optional. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements.

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2015
Acquisitions (Tables) [Line Items]
Business Acquisition, Pro Forma Information [Table Text Block]	Unaudited Pro Forma Results Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Revenue $ 54,805 $ 44,987 $ 100,247 $ 86,038 Net income (loss) $ 1,717 $ (600 ) $ (6,044 ) $ (8,498)
Estimate of Fair Value Measurement [Member]
Acquisitions (Tables) [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The following table summarizes the preliminary allocation of the assets acquired and liabilities assumed based on their fair values on the acquisition date. The fair values presented are based on a preliminary valuation and are subject to adjustment during a measurement period of up to one year from the acquisition date. The measurement period provides the Company with the ability to adjust the fair values of acquired assets for new information that is obtained about circumstances that existed as of the acquisition date. Accounts receivable $ 4,406 Other current assets 137 Property and equipment 783 Goodwill 15,576 Intangible assets 14,280 Accounts payable and accrued expenses (2,659 ) Deferred revenue (197 ) Other current liabilities (53 ) Total consideration paid $ 32,273

Goodwill and Other Intangible21

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Definite-lived intangible assets consist of the following: June 30, 2015 December 31, 2014 Gross carrying amount Accumulated amortization Net carrying amount Weighted- average remaining useful life (1) Gross carrying amount Accumulated amortization Net carrying amount Weighted- average remaining useful life (1) Customer relationships $ 37,580 $ (12,640 ) $ 24,940 9.3 $ 27,300 $ (11,247 ) $ 16,053 9.5 Trade names 24,085 (5,626 ) 18,459 7.1 18,615 (4,370 ) 14,245 6.5 Other intangibles 3,900 (3,761 ) 139 0.3 3,900 (3,482 ) 418 0.7 Total $ 65,565 $ (22,027 ) $ 43,538 $ 49,815 $ (19,099 ) $ 30,716 (1) The calculation of the weighted-average remaining useful life is based on weighting the net book value of each asset in its group, and applying the weight to its respective remaining amortization period.
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Future amortization expense of the intangible assets is estimated to be as follows: Year ending December 31: 2015 (July 1st to December 31st) $ 2,983 2016 5,520 2017 5,512 2018 5,323 2019 5,323 Thereafter 18,877 Total $ 43,538

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activity for the six months ended June 30, 2015: Number of options Weighted- average exercise price Weighted- average remaining contractual life (years) Aggregate intrinsic value Outstanding at December 31, 2014 5,893,698 $ 9.94 6.48 $ 29,249 Granted 785,150 12.24 Exercised (230,776 ) 7.48 Cancelled (167,002 ) 12.54 Outstanding at June 30, 2015 6,281,070 $ 10.26 5.79 $ 19,579 Exercisable at June 30, 2015 3,949,409 $ 8.62 4.32 $ 17,436
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following table presents the weighted-average assumptions used to estimate the fair value of options granted in the six months ended June 30, 2015 and 2014: 2015 2014 Volatility 44.06 % 49.74 % Expected life (years) 6.25 6.25 Risk-free interest rate 1.73 % 1.91 % Dividend yield — —
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	The following table summarizes the unvested RSU activity for the six months ended June 30, 2015: Number of Weighted Outstanding at December 31, 2014 — $ — Granted (1) 573,724 12.01 Vested (1,923 ) 11.99 Cancelled (24,397 ) 11.99 Outstanding at June 30, 2015 547,404 $ 12.01

Net Income (Loss) Attributabl23

Net Income (Loss) Attributable to Common Stockholders per Common Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The basic and diluted net income (loss) attributable to common stockholders per common share is calculated as follows for the periods presented: Three months ended Six months ended June 30, June 30, 2015 2014 2015 2014 Numerator: Net income (loss) $ 1,694 $ (595 ) $ (6,374 ) $ (8,354 ) Series G preferred stock deemed dividend — (8,079 ) — (8,079 ) Net income (loss) attributable to common stockholders $ 1,694 $ (8,674 ) $ (6,374 ) $ (16,433 ) Denominator: Weighted-average number of common shares outstanding for basic net income (loss) attributable to common stockholders per common share 31,755,107 29,802,970 31,640,967 17,670,809 Dilutive securities: Stock option awards 1,476,550 — — — Restricted stock units 97,232 — — — Warrants to purchase common stock 37,320 — — — Employee stock purchase plan 7,198 — — — Total weighted-average diluted shares 33,373,407 29,802,970 31,640,967 17,670,809 Basic net income (loss) attributable to common stockholders per common share $ 0.05 $ (0.29 ) $ (0.20 ) $ (0.93 ) Diluted net income (loss) attributable to common stockholders per common share $ 0.05 $ (0.29 ) $ (0.20 ) $ (0.93 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following securities were outstanding for the periods presented below and have been excluded from the calculation of diluted net income (loss) attributable to common stockholders per common share because the effect is anti-dilutive: Three months ended Six months ended June 30, June 30, 2015 2014 2015 2014 Warrants to purchase common stock (1) — 422,153 110,080 495,807 Warrants to purchase redeemable convertible preferred stock (1) — 148,650 — 148,650 Redeemable convertible preferred stock (1) — 589,456 — 13,632,402 Stock option awards 2,496,032 4,984,276 4,072,625 5,077,505 Unvested RSU awards — — 362,142 — Employee stock purchase plan — 21,140 50,444 10,628 Total weighted-average anti-dilutive securities 2,496,032 6,165,675 4,595,291 19,364,992 (1) Upon closing of the IPO on April 2, 2014, all of the Company's outstanding redeemable convertible preferred stock automatically converted into shares of common stock. In addition, the outstanding warrants to purchase redeemable convertible preferred stock automatically converted into warrants to purchase common stock, or were automatically exercised upon closing of the IPO.

Significant Accounting Polici24

Significant Accounting Policies (Details) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Apr. 30, 2014USD ($)$ / sharesshares	Mar. 31, 2014USD ($)	Jun. 30, 2015
Significant Accounting Policies (Details) [Line Items]
Debtor Reorganization Items, Write-off of Deferred Financing Costs and Debt Discounts		$ 2,845
Debt Prepayment Fees		1,016
Capital Units, Adjustment for Market Changes		$ 253
Number of Reportable Segments			1
IPO [Member]
Significant Accounting Policies (Details) [Line Items]
Proceeds from Issuance Initial Public Offering	$ 70,622
Payments for Underwriting Expense	$ 8,848
Common Stock, No Par Value (in Dollars per share) | $ / shares	$ 14
IPO [Member] | Common Stock [Member]
Significant Accounting Policies (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares) | shares	5,676,414
Convertible Preferred Stock, Shares Issued upon Conversion (in Shares) | shares	18,457,235
IPO [Member] | Series G Preferred Stock [Member]
Significant Accounting Policies (Details) [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion (in Shares) | shares	577,055
Software and Software Development Costs [Member]
Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives			three
Website And Mobile Applications [Member]
Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives			three
Minimum [Member]
Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives			three
Maximum [Member]
Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives			five

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 20, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Acquisitions (Details) [Line Items]
Payments to acquire business					$ (32,747)
Contingent Earn-out Provisions, Eligibility					5,000
Contingent Earn Out Provisions Expense Incurred					2,270
Revenues			$ 54,805	$ 41,447	95,980	$ 78,952
Net Income (Loss) Attributable to Parent			1,694	$ (595)	(6,374)	$ (8,354)
Business Combination, Acquisition Related Costs			$ 17		$ 186
Cambridge [Member]
Acquisitions (Details) [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired			100.00%		100.00%
Business Acquisition, Name of Acquired Entity					Cambridge BioMarketing Group, LLC
Business Combination, Consideration Transferred		$ 32,273
Revenues			$ 5,357		$ 6,045
Net Income (Loss) Attributable to Parent			$ 1,709		$ 1,987
Cambridge [Member] | Closing [Member]
Acquisitions (Details) [Line Items]
Payments to acquire business		$ 24,273
Cambridge [Member] | Remainder [Member]
Acquisitions (Details) [Line Items]
Due To Sellers Of Acquired Business	$ 8,000

Acquisitions (Details) - Pro fo

Acquisitions (Details) - Pro forma consolidated net sales and income from continuing operations - Pro Forma [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Acquisitions (Details) - Pro forma consolidated net sales and income from continuing operations [Line Items]
Revenue	$ 54,805	$ 44,987	$ 100,247	$ 86,038
Net income (loss)	$ 1,717	$ (600)	$ (6,044)	$ (8,498)

Acquisitions (Details) - Prelim

Acquisitions (Details) - Preliminary allocation of the assets acquired and liabilities assumed - USD ($) $ in Thousands	1 Months Ended
	Mar. 20, 2015	Jun. 30, 2015	Dec. 31, 2014
Acquisitions (Details) - Preliminary allocation of the assets acquired and liabilities assumed [Line Items]
Property and equipment		$ 25,915	$ 25,502
Goodwill		142,157	127,115
Intangible assets		43,538	30,716
Accounts payable and accrued expenses		28,360	31,722
Other current liabilities		921	$ 965
Cambridge [Member]
Acquisitions (Details) - Preliminary allocation of the assets acquired and liabilities assumed [Line Items]
Accounts receivable	$ 4,406
Other current assets	137
Property and equipment	783
Goodwill	15,576	$ 15,576
Intangible assets	14,280
Accounts payable and accrued expenses	(2,659)
Deferred revenue	(197)
Other current liabilities	(53)
Total consideration paid	$ 32,273

Goodwill and Other Intangible28

Goodwill and Other Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Mar. 20, 2015	Dec. 31, 2014
Goodwill and Other Intangible Assets (Details) [Line Items]
Goodwill	$ 142,157		$ 142,157			$ 127,115
Finite-Lived Intangible Assets, Net	43,538		43,538			30,716
Goodwill, Period Increase (Decrease)			534
Finite-Lived Intangible Assets, Period Increase (Decrease)			1,470
Amortization of Intangible Assets	1,709	$ 546	2,928	$ 1,091
Cambridge [Member]
Goodwill and Other Intangible Assets (Details) [Line Items]
Goodwill	15,576		15,576		$ 15,576
Finite-Lived Intangible Assets, Net	14,280		14,280
Customer Relationships [Member]
Goodwill and Other Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Assets, Net	24,940		24,940			16,053
Customer Relationships [Member] | Cambridge [Member]
Goodwill and Other Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Assets, Net	8,810		$ 8,810
Finite-Lived Intangible Asset, Useful Life			10 years
Trade Names [Member]
Goodwill and Other Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Assets, Net	18,459		$ 18,459			$ 14,245
Trade Names [Member] | Cambridge [Member]
Goodwill and Other Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Assets, Net	$ 5,470		$ 5,470
Finite-Lived Intangible Asset, Useful Life			10 years

Goodwill and Other Intangible29

Goodwill and Other Intangible Assets (Details) - Schedule of definite-lived intangible assets - USD ($) $ in Thousands		6 Months Ended	12 Months Ended
		Jun. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		$ 65,565	$ 49,815
Accumulated amortization		(22,027)	(19,099)
Net carrying amount		43,538	30,716
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		37,580	27,300
Accumulated amortization		(12,640)	(11,247)
Net carrying amount		$ 24,940	$ 16,053
Weighted- average remaining useful life	[1]	9 years 109 days	9 years 6 months
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		$ 24,085	$ 18,615
Accumulated amortization		(5,626)	(4,370)
Net carrying amount		$ 18,459	$ 14,245
Weighted- average remaining useful life	[1]	7 years 36 days	6 years 6 months
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		$ 3,900	$ 3,900
Accumulated amortization		(3,761)	(3,482)
Net carrying amount		$ 139	$ 418
Weighted- average remaining useful life	[1]	109 days	255 days
[1]	The calculation of the weighted-average remaining useful life is based on weighting the net book value of each asset in its group, and applying the weight to its respective remaining amortization period.

Goodwill and Other Intangible30

Goodwill and Other Intangible Assets (Details) - Schedule of future amortization expense of intangible assets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Schedule of future amortization expense of intangible assets [Abstract]
2015 (July 1st to December 31st)	$ 2,983
2,016	5,520
2,017	5,512
2,018	5,323
2,019	5,323
Thereafter	18,877
Total	$ 43,538	$ 30,716

Long-Term Debt (Details)

Long-Term Debt (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Mar. 31, 2015	Mar. 01, 2015	Nov. 30, 2014	Nov. 01, 2014	Mar. 31, 2014
Long-Term Debt (Details) [Line Items]
Credit Facility Rate Description	The interest rate on the Credit Facility is equal to the London Inter-Bank Offered Rate, or LIBOR, plus a variable rate ranging from 2.75% to 4.0% depending on the Company’s consolidated leverage ratio, as defined in the Credit Facility agreement, and there is a 0.50% commitment fee on the unused portion of the Revolver.
Payments of Financing Costs	$ 722	$ 722	$ 2,234	$ 2,899
Revolving Credit Facility [Member]
Long-Term Debt (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity					$ 82,250				$ 35,000
Credit Facility, Outstanding Balance	$ 45,000	45,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.50%
Line of Credit Facility, Remaining Borrowing Capacity	$ 37,250	37,250
Term Loan Facility [Member]
Long-Term Debt (Details) [Line Items]
Credit Facility Maximum Borrowing Capacity									$ 40,000
Credit Facility, Outstanding Balance	$ 67,750	$ 67,750			$ 67,750	$ 59,250
Credit Facility [Member]
Long-Term Debt (Details) [Line Items]
Credit Facility Rate Monthly	4.28%
DD [Member] | Revolving Credit Facility [Member]
Long-Term Debt (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity							$ 55,000
DD [Member] | Term Loan Facility [Member]
Long-Term Debt (Details) [Line Items]
Credit Facility, Outstanding Balance							$ 60,000	$ 39,000
Minimum [Member] | Credit Facility [Member]
Long-Term Debt (Details) [Line Items]
Credit Facility Rate Monthly	2.75%
Maximum [Member] | Credit Facility [Member]
Long-Term Debt (Details) [Line Items]
Credit Facility Rate Monthly	4.00%

Common Stock and Preferred St32

Common Stock and Preferred Stock (Details) - shares	3 Months Ended
	Mar. 31, 2014	Jun. 30, 2015	Dec. 31, 2014	Apr. 30, 2014
Stockholders' Equity Note [Abstract]
Preferred Stock, Shares Issued		0	0
Preferred Stock, Shares Outstanding		0	0
Stockholders' Equity, Reverse Stock Split	In March 2014, the Company’s Board of Directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation effecting a 1-for-1.5 reverse stock split of the Company’s issued and outstanding shares of common stock. The par value of the common stock was not adjusted as a result of the reverse stock split. All issued and outstanding common stock and per share amounts contained in the Company’s consolidated financial statements and related notes thereto have been retroactively adjusted to reflect this reverse stock split for all periods presented. The reverse stock split was effected on March 14, 2014.
Common Stock, Shares Authorized		90,000,000	90,000,000	90,000,000
Preferred Stock, Shares Authorized		10,000,000	10,000,000	10,000,000

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Apr. 30, 2014	Mar. 27, 2014
Stock-Based Compensation (Details) [Line Items]
Proceeds from Stock Options Exercised		$ 1,309	$ 983	$ 1,769	$ 2,151
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		792	2,312	$ 1,276	$ 3,225
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)				$ 5.48	$ 7.68
Allocated Share-based Compensation Expense		1,511	2,543	$ 3,469	$ 3,612
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 6,835		6,835
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		1 year 135 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				$ 3,668	1,974
Common Stock, Shares Authorized (in Shares)		90,000,000		90,000,000		90,000,000	90,000,000
2014 Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance (in Shares)		440,210		440,210
Common stock, number of shares reserved for issuance, description		The number of shares of common stock reserved for issuance under the 2014 Plan is subject to an automatic increase on January 1 of each year through January 1, 2024, by the lesser of (a) 4% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year and (b) a number of shares determined by the Board of Directors.
Employee Stock [Member]
Stock-Based Compensation (Details) [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance (in Shares)		567,403		567,403
Common stock, number of shares reserved for issuance, description		The number of shares of common stock reserved for issuance under the ESPP will automatically increase on January 1 of each calendar year from January 1, 2015 through January 1, 2024 by the least of (a) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (b) 400,000 shares and (c) a number determined by the Board of Directors that is less than (a) and (b).
Allocated Share-based Compensation Expense		$ (20)	$ 407	$ 251	$ 407
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 365		$ 365
Common Stock, Shares Authorized (in Shares)								500,000
Common stock, purchase for participating employee price, description		Unless otherwise determined by the Board of Directors, common stock will be purchased for participating employees at a price per share equal to the lower of (a) 85% of the fair market value of a share of the common stock on the first date of an offering, or (b) 85% of the fair market value of a share of the common stock on the date of purchase.
Contribution Percentage		15.00%
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares)		109,304,000
Employee Stock Purchase Plan Purchase Price (in Dollars per share)		$ 10.51		$ 10.51
Performance RSU [Member]
Stock-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)		40,000
Restricted Stock Units (RSUs) [Member]
Stock-Based Compensation (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		1 year 138 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)	[1]			573,724
Restricted Stock or Unit Expense		$ 1,261		$ 1,524
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 4,706		$ 4,706
[1]	RSUs granted during the six months ended June 30, 2015 includes the grant of 40,000 units of performance-based RSUs that are dependent upon the Company meeting certain performance criteria.

Stock-Based Compensation (Det34

Stock-Based Compensation (Details) - Schedule of stock option activity - Stock Option Activity [Member] - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2014	Jun. 30, 2015
Stock-Based Compensation (Details) - Schedule of stock option activity [Line Items]
Number of options	5,893,698
Weighted-average exercise price	$ 9.94
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	6 years 175 days	5 years 288 days
Aggregate intrinsic value	$ 29,249
Exercisable at June 30, 2015		3,949,409
Exercisable at June 30, 2015		$ 8.62
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2		4 years 116 days
Exercisable at June 30, 2015		$ 17,436
Granted		785,150
Granted		$ 12.24
Exercised		(230,776)
Exercised		$ 7.48
Cancelled		(167,002)
Cancelled		$ 12.54
Number of options		6,281,070
Weighted-average exercise price		$ 10.26
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	6 years 175 days	5 years 288 days
Aggregate intrinsic value		$ 19,579

Stock-Based Compensation (Det35

Stock-Based Compensation (Details) - Schedule of weighted-average assumptions - $ / shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Schedule of weighted-average assumptions [Abstract]
Volatility	44.06%	49.74%
Expected life (years)	6 years 3 months	6 years 3 months
Risk-free interest rate	1.73%	1.91%
Dividend yield (in Dollars per share)	$ 0	$ 0

Stock-Based Compensation (Det36

Stock-Based Compensation (Details) - Schedule of restricted stock unit awards - Jun. 30, 2015 - Restricted Stock Units (RSUs) [Member] - $ / shares		Total
Stock-Based Compensation (Details) - Schedule of restricted stock unit awards [Line Items]
Outstanding, Number of RSUs		0
Outstanding, Weighted Average Grant Date Fair Value		$ 0
Granted (1)	[1]	573,724
Granted (1)	[1]	$ 12.01
Vested		(1,923)
Vested		$ 11.99
Cancelled		(24,397)
Cancelled		$ 11.99
Outstanding, Number of RSUs		547,404
Outstanding, Weighted Average Grant Date Fair Value		$ 12.01
[1]	RSUs granted during the six months ended June 30, 2015 includes the grant of 40,000 units of performance-based RSUs that are dependent upon the Company meeting certain performance criteria.

Net Income (Loss) Attributabl37

Net Income (Loss) Attributable to Common Stockholders per Common Share (Details) - Basic and diluted net income (loss) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Numerator:
Net income (loss) (in Dollars)	$ 1,694	$ (595)	$ (6,374)	$ (8,354)
Series G preferred stock deemed dividend (in Dollars)		(8,079)		(8,079)
Net income (loss) attributable to common stockholders (in Dollars)	$ 1,694	$ (8,674)	$ (6,374)	$ (16,433)
Denominator:
Weighted-average number of common shares outstanding for basic net income (loss) attributable to common stockholders per common share	31,755,107	29,802,970	31,640,967	17,670,809
Dilutive securities:
Warrants to purchase common stock	37,320
Total weighted-average diluted shares	33,373,407	29,802,970	31,640,967	17,670,809
Basic net income (loss) attributable to common stockholders per common share (in Dollars per share)	$ 0.05	$ (0.29)	$ (0.20)	$ (0.93)
Diluted net income (loss) attributable to common stockholders per common share (in Dollars per share)	$ 0.05	$ (0.29)	$ (0.20)	$ (0.93)
2014 Plan [Member]
Dilutive securities:
Stock option awards	1,476,550
Restricted Stock Units (RSUs) [Member]
Dilutive securities:
Stock option awards	97,232
Employee Stock [Member]
Dilutive securities:
Stock option awards	7,198

Net Income (Loss) Attributabl38

Net Income (Loss) Attributable to Common Stockholders per Common Share (Details) - Securities excluded from calculations of diluted net loss per common share - shares		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		2,496,032	6,165,675	4,595,291	19,364,992
Common Stock Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	[1]		422,153	110,080	495,807
Preferred Stock Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	[1]		148,650		148,650
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	[1]		589,456		13,632,402
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		2,496,032	4,984,276	4,072,625	5,077,505
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities				362,142
Employee Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities			21,140	50,444	10,628
[1]	Upon closing of the IPO on April 2, 2014, all of the Company's outstanding redeemable convertible preferred stock automatically converted into shares of common stock. In addition, the outstanding warrants to purchase redeemable convertible preferred stock automatically converted into warrants to purchase common stock, or were automatically exercised upon closing of the IPO.

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Income Taxes (Details) [Line Items]
Income Tax Expense (Benefit)	$ (5,534)	$ 349	$ (6,451)	$ 638
Current Income Tax Expense (Benefit)	$ 5,534		6,451
Operating Loss Carryforwards					$ 107,000
DD [Member]
Income Taxes (Details) [Line Items]
Income Tax Expense (Benefit)			$ 601
Deferred Compensation, Share-based Payments [Member]
Income Taxes (Details) [Line Items]
Operating Loss Carryforwards					$ 7,433

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Thousands	Aug. 06, 2015	Jun. 30, 2015
Subsequent Events (Details) [Line Items]
Payments to acquire business		$ (32,747)
Contingent Earn-out Provisions, Eligibility		$ 5,000
TL [Member]
Subsequent Events (Details) [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Business Combination, Consideration Transferred	$ 30,000
Contingent Earn-out Provisions, Eligibility	20,000
TL [Member] | Paid At Closing [Member]
Subsequent Events (Details) [Line Items]
Payments to acquire business	15,000
TL [Member] | Paid Within Six Months[Member]
Subsequent Events (Details) [Line Items]
Due To Sellers Of Acquired Business	$ 15,000
TL [Member] | Payment Method, Cash [Member]
Subsequent Events (Details) [Line Items]
Contingent Earn Out Provisions Percentage	50.00%
TL [Member] | Payment Method, Shares [Member]
Subsequent Events (Details) [Line Items]
Contingent Earn Out Provisions Percentage	50.00%